ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Buy” from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned an average rating of “Buy” from the nine analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $79.75.

ANIP has been the topic of several research reports. Guggenheim lifted their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 3rd. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th.

Insider Buying and Selling

In related news, VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares in the company, valued at $4,131,164.80. The trade was a 1.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,700 shares of company stock valued at $610,201. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV increased its holdings in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after buying an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of ANI Pharmaceuticals in the 4th quarter worth $166,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after buying an additional 579 shares during the last quarter. Finally, Rafferty Asset Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at $200,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $62.49 on Wednesday. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of 0.62. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The firm’s 50-day simple moving average is $58.40 and its two-hundred day simple moving average is $58.06.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.